RxDoctor Payments Data

Jessica Ojeda

Acute Care · la Junta, CONPI 1033706247

Payments from drug & device makers

$788in general payments, 2019–2025

Across 39 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$263
  • AbbVie$201
  • Novo Nordisk$56
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$53
  • Viatris Specialty LLC$38
  • Exact Sciences$36
  • plus $142 from 6 others

What the payments were for

  • Food & beverage$788100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$788 in reported general payments places this provider in the 70th percentile of 239 acute care providers in Colorado.

See all acute care providers in Colorado

Medicare billing

Part B allowed, 2024
$91,274
Medicare patients
136
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$136,585
MounjaroTirzepatide65$74,612
EliquisApixaban56$72,137
TrulicityDulaglutide44$69,208
KevzaraSarilumab15$66,667
JanuviaSitagliptin Phosphate37$49,931
Repatha SureclickEvolocumab61$45,110
VraylarCariprazine Hcl25$41,847
TradjentaLinagliptin22$34,460
Advair HfaFluticasone Propion/Salmeterol47$25,014
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$23,553
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$20,473
XareltoRivaroxaban21$19,959
JardianceEmpagliflozin11$19,483
Repatha SyringeEvolocumab24$17,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$25$143,821109 claims
Novo NordiskOzempic$56$136,585127 claims
AbbVieVraylar$201$41,84725 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$20$39,52644 claims
Astellas Pharma US IncMyrbetriq$16$16,60211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 239 acute care providers in Colorado.

Other acute care in la Junta

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →